Effective 03/15/2026, BCBS Louisiana’s AHS‑G2121 policy designates fecal calprotectin as the preferred fecal biomarker for distinguishing IBD from noninflammatory GI disease and for monitoring IBD therapy response or relapse; when both fecal calprotectin and fecal lactoferrin are ordered concurrently, only fecal calprotectin will be approved. Fecal calprotectin or lactoferrin meet coverage criteria only for (a) differentiating IBD from noninflammatory conditions (e.g., IBS) and (b) monitoring known IBD; all other uses do not meet coverage criteria. Serologic markers, genetic tests, multianalyte serum panels, and combinatorial serologic‑genetic algorithms (e.g., Prometheus®, IBSchek®, etc.) are expressly non‑covered due to insufficient evidence of clinical utility. The policy aligns with AGA/ACG/ECCO/NICE/BSG guidance favoring fecal calprotectin while advising against routine serologic/genetic testing for IBD diagnosis or classification.
March 15, 2026 Revision: Effective Date and Preferred Biomarker Clarification
This revision updates the Current Effective Date to 03/15/2026 for Blue Cross and Blue Shield of Louisiana policy AHS - G2121 titled "Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease." The document restates the policy structure (Policy Description, Indications and/or Limitations of Coverage, Scientific Background, Guidelines, and References) and emphasizes fecal calprotectin as the preferred fecal biomarker (Note 1). The policy clarifies that when both fecal calprotectin and fecal lactoferrin are ordered concurrently, only fecal calprotectin will be approved.
No new CPT/HCPCS procedure codes or state-specific regulatory changes are listed in the visible revision text. The revised document continues to reference related policies (AHS-G2043, AHS-G2060, AHS-G2155) and updates the effective date while maintaining prior coverage determinations described in the Indications and/or Limitations of Coverage section.
Coverage Scope: Fecal Calprotectin/Lactoferrin — Indications and Limits
The policy defines covered and non-covered laboratory testing for IBD diagnostic workup and monitoring. It states that fecal calprotectin or fecal lactoferrin testing "MEETS COVERAGE CRITERIA" for two specific situations: (a) differentiating non-inflammatory gastrointestinal disease (e.g., IBS) from inflammatory disease (e.g., IBD), and (b) monitoring individuals with IBD to assess response to therapy or relapse. However, Note 1 specifies fecal calprotectin as the preferred biomarker and indicates that if both tests are ordered simultaneously, only fecal calprotectin will be approved.
For all other situations not described above, fecal calprotectin and fecal lactoferrin testing "DOES NOT MEET COVERAGE CRITERIA." This establishes a narrow coverage scope tied to differential diagnosis and disease monitoring.
Explicit Non-Coverage: Serologic, Genetic, and Multianalyte Panels
The policy explicitly denies coverage for multiple classes of tests related to IBD diagnosis and monitoring. It states that serologic markers (examples given include ANCA, pANCA, ASCA, anti-CBir1, OmpC, antiglycan tests such as ACCA/ALCA/AMCA, and serum pyruvate kinase M2) "DOES NOT MEET COVERAGE CRITERIA." Additionally, multianalyte serum biomarker panels and combinatorial serologic-genetic algorithms (examples cited: ibs-smart™, IBSchek®, Prometheus®) also "DO NOT MEET COVERAGE CRITERIA."
The policy frames these non-covered tests as lacking sufficient published evidence that they are required and beneficial for diagnosis or treatment, consistent with the Scientific Background sections that summarize limited or variable diagnostic utility, modest predictive value, and guideline recommendations against routine serologic/genetic testing for IBD diagnosis.
Evidence Basis: Fecal Calprotectin Strength vs. Limited Serologic/Genetic Utility
The Scientific Background and Clinical Utility sections collate evidence and guideline positions that underlie the coverage determinations. Fecal calprotectin is characterized as a well-validated fecal biomarker: multiple meta-analyses reported pooled sensitivity and specificity often >90% for distinguishing IBD from IBS at cutoffs around 50 µg/g, with alternative cutoffs (e.g., 100–150 µg/g) discussed for different clinical contexts. The policy cites guideline recommendations from organizations including the AGA, ACG, ECCO, NICE, and BSG that support fecal calprotectin (or lactoferrin) for initial screening and monitoring, while cautioning about assay variability and cutoff selection.
By contrast, the document summarizes inconsistent or limited clinical utility for serologic markers and genetic testing: ASCA and pANCA are noted as specific but not sensitive; antiglycan and anti-microbial antibodies have small incremental diagnostic value; and genetic markers have low predictive value for routine clinical use. The policy references studies validating multi-marker panels and gene-expression classifiers but treats these as investigational or not sufficient to meet coverage criteria.
Guideline Alignment: Professional Society Positions Reflected in Coverage Decisions
The policy aligns its coverage stance with multiple professional guideline statements summarized in the document. It notes that AGA and ACG guidance endorse fecal calprotectin (and fecal lactoferrin) for differentiating inflammatory from noninflammatory disease and for monitoring UC and CD activity, while recommending against routine use of serologic antibody testing to establish diagnosis or prognosis. ECCO, NICE, and BSG similarly endorse fecal calprotectin as part of initial investigation and follow-up, but advise against routine genetic or serological testing for classification or routine diagnosis.
These guideline summaries are used in the policy to justify permitting fecal calprotectin/lactoferrin in defined scenarios and to deny coverage for serologic, genetic, and proprietary multianalyte panels that lack consensus guideline support or sufficient validated clinical utility.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.